Key Takeaways Moderna projects Q2 sales of $127 million and a$2.99 per-share loss ahead of its Aug. 1 earnings release.Spikevax sales are estimated to decline sharply, with limited revenue from the RSV vaccine, mResvia.Investors await news on vaccine label expansions, regulatory filings, and late-stage trial results.We expect Moderna (MRNA) to surpass expectations when it reports second-quarter 2025 earnings on Aug. 1, before the opening bell. The company’s earnings beat estimates by 13.70% in the last rep ...